Systemic therapy in metastatic renal cell carcinoma.
2017
Purpose
Current systemic treatment of targeted therapies, namely the vascular endothelial growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitors, have improved progression-free survival and replaced non-specific immunotherapy with cytokines in metastatic renal cell carcinoma (mRCC).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
41
References
82
Citations
NaN
KQI